基于“虚气留滞”探讨线粒体功能障碍在原发性肝癌中的作用及中医药干预策略

刘晓丽; 黄晶晶; 黄鸿娜; 毛德文; 陈焕灵; 罗玲玲; 卢露; 余洁; 黄晶

doi:10.12449/JCH251228

基于“虚气留滞”探讨线粒体功能障碍在原发性肝癌中的作用及中医药干预策略

DOI: 10.12449/JCH251228

刘晓丽¹,
黄晶晶^{2, 3, , ,},
黄鸿娜^{2, 3},
毛德文^{2, 3},
陈焕灵¹,
罗玲玲¹,
卢露¹,
余洁¹,
黄晶¹

1.
广西中医药大学研究生院，南宁 530200
2.
广西高发传染病中西医结合转化医学重点实验室，南宁 530200
3.
广西中医药大学第一附属医院，南宁 530023

基金项目:

国家自然科学基金 (82460957);

广西自然科学基金 (2022GXNSFAA035460);

广西自然科学基金 (2024GXNSFDA010005);

广西自然科学基金 (2024GXNSFAA010078);

广西中医药大学引进博士科研启动基金 (2022BS026);

广西中医药大学青年创新研究团队项目 (2023TD004);

桂派中医药传承创新团队-疑难重症中医诊疗研究团队 (2022A001)

利益冲突声明：本文不存在任何利益冲突。

作者贡献声明：黄晶晶负责研究思路的设计；余洁、卢露负责查阅相关文献；陈焕灵、黄晶、罗玲玲负责资料归纳、分析；刘晓丽负责撰写论文及绘图；毛德文、黄鸿娜负责指导修改论文及最后定稿。

详细信息

通信作者:
黄晶晶， 55869563@qq.com（ORCID： 0000-0002-4936-0838）

计量
- 文章访问数: 20
- HTML全文浏览量: 9
- PDF下载量: 9
- 被引次数: 0
出版历程
- 收稿日期: 2025-05-02
- 录用日期: 2025-07-15
- 出版日期: 2025-12-25

Role of mitochondrial dysfunction in primary liver cancer and related traditional Chinese medicine intervention strategies： An analysis based on “deficient Qi retention and stagnation”

Xiaoli LIU¹,
Jingjing HUANG^{2, 3
, ,
,},
Hongna HUANG^{2, 3},
Dewen MAO^{2, 3},
Huanling CHEN¹,
Lingling LUO¹,
Lu LU¹,
Jie YU¹,
Jing HUANG¹

1.
Graduate School of Guangxi University of Chinese Medicine，Nanning 530200，China
2.
Guangxi Key Laboratory of Translational Medicine for Treating High-Incidence Infectious Diseases with Integrative Medicine，Nanning 530200，China
3.
The First Affiliated Hospital of Guangxi University of Chinese Medicine，Nanning 530023，China

Research funding:

National Natural Science Foundation of China (82460957);

Natural Science Foundation of Guangxi (2022GXNSFAA035460);

Natural Science Foundation of Guangxi (2024GXNSFDA010005);

Natural Science Foundation of Guangxi (2024GXNSFAA010078);

Guangxi University of Chinese Medicine Doctoral Research Start-up Fund Project (2022BS026);

Youth Innovation Research Team Project of Guangxi University of Chinese Medicine (2023TD004);

Guipai Traditional Chinese Medicine Inheritance and Innovation Team-Research Team for Diagnosis and Treatment of Difficult and Severe Cases with Traditional Chinese Medicine (2022A001)

More Information

Corresponding author: HUANG Jingjing， 55869563@qq.com （ORCID： 0000-0002-4936-0838）

摘要

摘要: 原发性肝癌是全球高发恶性肿瘤，当前治疗手段有限且疗效存在个体性差异，亟需探索新的治疗途径。中医学在肝癌治疗中具有独特优势，“虚气留滞”是重要的辩证理论之一。该理论认为，肝癌的发生发展与气虚、气滞密切相关，尤其是“虚气留滞”可导致肝脏气血失调，进而影响肝功能和代谢。近年研究发现，线粒体在细胞能量代谢、氧化应激和细胞凋亡等方面发挥关键作用，线粒体功能异常与肝癌的发生和进展密切相关。本文结合“虚气留滞”理论与线粒体功能相关的最新研究，探讨二者在原发性肝癌中的关联和作用，总结中医药调节线粒体功能干预原发性肝癌的研究进展，为未来的临床研究提供参考。
- 肝肿瘤 /
- 气虚 /
- 血瘀气滞 /
- 痰郁 /
- 线粒体 /
- 中医药疗法
Abstract: Primary liver cancer is a highly prevalent malignant tumor worldwide， with limited treatment options and individual difference in treatment outcome， and therefore， there is an urgent need to explore new treatment strategies. Traditional Chinese medicine （TCM） has unique advantages in the treatment of liver cancer， and “deficient Qi retention and stagnation” is one of the important syndrome differentiation-based theories. Based on this theory， it is believed that the development and progression of liver cancer are closely associated with Qi deficiency and Qi stagnation， and in particular， “deficient Qi retention and stagnation” can lead to Qi-blood disharmony in the liver， thereby impairing liver function and metabolism. Recent years have shown that mitochondria play a pivotal role in cellular energy metabolism， oxidative stress， and cell apoptosis， and abnormal mitochondrial function is closely associated with the development and progression of liver cancer. With reference to the latest research advances in the theory of “deficient Qi retention and stagnation” and mitochondrial function， this article discusses their association and role in primary liver cancer and summarizes the research advances in TCM treatment of primary liver cancer by regulating mitochondrial function， in order to provide a reference for future clinical studies.
- Liver Neoplasms /
- Syndrome of Qi Deficiency /
- Syndrome of Blood Stasis and Qi Stagnation /
- Syndrome of Phlegm Depression /
- Mitochondria /
- Traditional Chinese Medicine Therapy

HTML全文

图 1 中医药调节线粒体功能干预原发性肝癌的作用机制

Figure 1. The mechanism underlying the regulation of mitochondrial function by traditional Chinese medicine in the intervention of primary liver cancer

下载: 全尺寸图片幻灯片

参考文献(40)

[1]	RUMGAY H, ARNOLD M, FERLAY J, et al. Global burden of primary liver cancer in 2020 and predictions to 2040[J]. J Hepatol, 2022, 77( 6): 1598- 1606. DOI: 10.1016/j.jhep.2022.08.021.
[2]	SUNG H, FERLAY J, SIEGEL RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA A Cancer J Clin, 2021, 71( 3): 209- 249. DOI: 10.3322/caac.21660.
[3]	National Health Commission of the People's Republic of China. Standardization for Diagnosis and Treatment of Primary Hepatic Carcinoma(2024 Edition)[J]. J Clin Hepatol, 2024, 40( 5): 893- 918. DOI: 10.12449/JCH240508. 中华人民共和国国家卫生健康委员会. 原发性肝癌诊疗指南(2024年版)[J]. 临床肝胆病杂志, 2024, 40( 5): 893- 918. DOI: 10.12449/JCH240508.
[4]	HUANG SJ, WANG YY. Pathogenesis of ischemia leukoencephalopathy: Deficient-qi stagnation[J]. J Beijing Univ Tradit Chin Med, 2011, 34( 8): 513- 516. 黄世敬, 王永炎. 缺血性脑白质病变"虚气留滞"病机探讨[J]. 北京中医药大学学报, 2011, 34( 8): 513- 516.
[5]	LI XH, YUAN HX. Improving the efficacy of traditional Chinese medicine in treatment of primary liver cancer based on etiology and pathogenesis[J]. J Clin Hepatol, 2021, 37( 9): 2001- 2004. DOI: 10.3969/j.issn.1001-5256.2021.09.001. 李秀惠, 袁慧鑫. 从病因病机入手提高中医药治疗原发性肝癌的疗效[J]. 临床肝胆病杂志, 2021, 37( 9): 2001- 2004. DOI: 10.3969/j.issn.1001-5256.2021.09.001.
[6]	XU CY, ZHANG GJ. Discussion on the pathogenesis of liver cancer from the pathogenesis theory of'blood stasis and toxin interaction'[J]. China J Tradit Chin Med Pharm, 2023, 38( 4): 1469- 1472. 徐楚韵, 张光霁. 试从"瘀毒互结"病机理论探析肝癌的发病机制[J]. 中华中医药杂志, 2023, 38( 4): 1469- 1472.
[7]	HORBAY R, BILYY R. Mitochondrial dynamics during cell cycling[J]. Apoptosis, 2016, 21( 12): 1327- 1335. DOI: 10.1007/s10495-016-1295-5.
[8]	DAN DUNN J, ALVAREZ LA, ZHANG XZ, et al. Reactive oxygen species and mitochondria: A nexus of cellular homeostasis[J]. Redox Biol, 2015, 6: 472- 485. DOI: 10.1016/j.redox.2015.09.005.
[9]	WU D, YANG Y, HOU YR, et al. Increased mitochondrial fission drives the reprogramming of fatty acid metabolism in hepatocellular carcinoma cells through suppression of Sirtuin 1[J]. Cancer Commun, 2022, 42( 1): 37- 55. DOI: 10.1002/cac2.12247.
[10]	MOORE MP, CUNNINGHAM RP, MEERS GM, et al. Compromised hepatic mitochondrial fatty acid oxidation and reduced markers of mitochondrial turnover in human NAFLD[J]. Hepatology, 2022, 76( 5): 1452- 1465. DOI: 10.1002/hep.32324.
[11]	LI PA, HOU XL, HAO SC. Mitochondrial biogenesis in neurodegeneration[J]. J Neurosci Res, 2017, 95( 10): 2025- 2029. DOI: 10.1002/jnr.24042.
[12]	SHI C, CAI Y, LI YH, et al. Yap promotes hepatocellular carcinoma metastasis and mobilization via governing cofilin/F-actin/lamellipodium axis by regulation of JNK/Bnip3/SERCA/CaMKII pathways[J]. Redox Biol, 2018, 14: 59- 71. DOI: 10.1016/j.redox.2017.08.013.
[13]	CHEN P, YAO LC, YUAN MQ, et al. Mitochondrial dysfunction: A promising therapeutic target for liver diseases[J]. Genes Dis, 2024, 11( 3): 101115. DOI: 10.1016/j.gendis.2023.101115.
[14]	HARRINGTON JS, RYTER SW, PLATAKI M, et al. Mitochondria in health, disease, and aging[J]. Physiol Rev, 2023, 103( 4): 2349- 2422. DOI: 10.1152/physrev.00058.2021.
[15]	LI GD, LI GJ, LI L, et al. Exploring the biological basis of Qi Deficiency based on mitochondrial dysfunction[J]. Glob Tradit Chin Med, 2023, 16( 9): 1844- 1847. DOI: 10.3969/j.issn.1674-1749.2023.09.023. 李国栋, 李改杰, 李丽, 等. 基于线粒体功能障碍探讨气虚的生物学基础[J]. 环球中医药, 2023, 16( 9): 1844- 1847. DOI: 10.3969/j.issn.1674-1749.2023.09.023.
[16]	GAO XQ, ZUO S, JIA XD, et al. Association between mitochondrial dysfunction and hepatocellular carcinoma[J]. J Clin Hepatol, 2022, 38( 6): 1436- 1439. DOI: 10.3969/j.issn.1001-5256.2022.06.045. 高小强, 左石, 贾晓东, 等. 线粒体功能障碍与肝细胞癌的关系[J]. 临床肝胆病杂志, 2022, 38( 6): 1436- 1439. DOI: 10.3969/j.issn.1001-5256.2022.06.045.
[17]	CHEN P, YAO LC, YUAN MQ, et al. Mitochondrial dysfunction: A promising therapeutic target for liver diseases[J]. Genes Dis, 2024, 11( 3): 101115. DOI: 10.1016/j.gendis.2023.101115.
[18]	SONG BS, MOON JS, TIAN JW, et al. Mitoribosomal defects aggravate liver cancer via aberrant glycolytic flux and T cell exhaustion[J]. J Immunother Cancer, 2022, 10( 5): e004337. DOI: 10.1136/jitc-2021-004337.
[19]	LEE HY, NGA HT, TIAN JW, et al. Mitochondrial metabolic signatures in hepatocellular carcinoma[J]. Cells, 2021, 10( 8): 1901. DOI: 10.3390/cells10081901.
[20]	LI Z, WANG K, WANG KQ, et al. Research progress on mitochondrial prevention and treatment of liver cancer mediated by traditional Chinese medicine[J]. Chin Tradit Herb Drugs, 2022, 53( 2): 575- 589. DOI: 10.7501/j.issn.0253-2670.2022.02.028. 李振, 王科, 王凯强, 等. 中药介导线粒体防治肝癌的研究进展[J]. 中草药, 2022, 53( 2): 575- 589. DOI: 10.7501/j.issn.0253-2670.2022.02.028.
[21]	WANG JX, SONG N, WANG J, et al. Effect and mechanism of ginsenoside Rb1 on hepatocellular carcinoma through apolipoprotein M/mitochondrial apoptosis pathway[J]. World Chin Med, 2024, 19( 17): 2578- 2583. DOI: 10.3969/j.issn.1673-7202.2024.17.006. 王嘉鑫, 宋囡, 王杰, 等. 人参皂苷Rb1通过载脂蛋白M/线粒体凋亡途径对肝癌的影响及机制研究[J]. 世界中医药, 2024, 19( 17): 2578- 2583. DOI: 10.3969/j.issn.1673-7202.2024.17.006.
[22]	ZHANG HR, QIAN M, LI M. Astragalus polysaccharides inhibit hepatocellular carcinoma cells through mitochondrial autophagy[J]. Northwest Pharm J, 2021, 36( 3): 426- 429. DOI: 10.3969/j.issn.1004-2407.2021.03.017. 张慧蓉, 钱敏, 李萌. 黄芪多糖通过线粒体自噬抑制肝癌肿瘤细胞[J]. 西北药学杂志, 2021, 36( 3): 426- 429. DOI: 10.3969/j.issn.1004-2407.2021.03.017.
[23]	LI JN. Fuzheng Qingjie recipe induces apoptosis of hepatoma cancer cells through mitochondrial apoptosis pathway[D]. Fuzhou: Fujian University of Traditional Chinese Medicine, 2014. 黎金浓. 扶正清解方通过线粒体凋亡通路诱导肝癌细胞凋亡的机制研究[D]. 福州: 福建中医药大学, 2014.
[24]	ZHAO JR, FENG XS, LI H, et al. Effect of Sini San prescription on apoptosis and proliferation of hepatocellular carcinoma HepG2 cells[J]. Chin J Appl Physiol, 2020, 36( 5): 489- 493. DOI: 10.12047/j.cjap.5839.2020.104. 赵家荣, 冯雪松, 李宏, 等. 四逆散对人肝癌HepG2细胞增殖、凋亡的影响及其机制[J]. 中国应用生理学杂志, 2020, 36( 5): 489- 493. DOI: 10.12047/j.cjap.5839.2020.104.
[25]	LI HJ, YANG J, JIANG Y, et al. Effects of Shenmai injection on proliferation and apoptosis of p53-deficient Hep3B cells[J]. Chin Arch Tradit Chin Med, 2016, 34( 10): 2500- 2503. DOI: 10.13193/j.issn.1673-7717.2016.10.055. 李红娟, 杨军, 姜英, 等. 参麦注射液对p53缺失Hep3B细胞增殖及凋亡的影响[J]. 中华中医药学刊, 2016, 34( 10): 2500- 2503. DOI: 10.13193/j.issn.1673-7717.2016.10.055.
[26]	LIU D, LIU M, JIN LY, et al. Research progress on the antitumor activity of costunolide[J]. Chin J Clin Pharmacol Ther, 2023, 28( 10): 1168- 1176. DOI: 10.12092/j.issn.1009-2501.2023.10.011. 刘丹, 刘明, 金良友, 等. 木香烃内酯抗肿瘤活性研究进展[J]. 中国临床药理学与治疗学, 2023, 28( 10): 1168- 1176. DOI: 10.12092/j.issn.1009-2501.2023.10.011.
[27]	CHAO X, LI H, WANG GQ, et al. Research on molecular mechanism of the apoptosis of human liver cancer SMMC-7721 cells induced by peiminine[J]. West J Tradit Chin Med, 2020, 33( 3): 26- 29. DOI: 10.12174/j.issn.1004-6852.2020.03.07. 晁旭, 李宏, 王国全, 等. 贝母素乙诱导人肝癌SMMC-7721细胞凋亡的分子机制研究[J]. 西部中医药, 2020, 33( 3): 26- 29. DOI: 10.12174/j.issn.1004-6852.2020.03.07.
[28]	BI L, YAN XJ, CHEN WP, et al. Antihepatocellular carcinoma potential of tetramethylpyrazine induces cell cycle modulation and mitochondrial-dependent apoptosis: Regulation of p53 signaling pathway in HepG2 cells in vitro[J]. Integr Cancer Ther, 2016, 15( 2): 226- 236. DOI: 10.1177/1534735416637424.
[29]	LI J, GAO L, CHEN SS, et al. Effect of Jianpi Huoxue Qushi Decoction on regulating mitochondrial apoptosis pathway by intervening AQP9 expression on nude mice with H22 liver cancer transplantation[J]. Chin Arch Tradit Chin Med, 2020, 38( 5): 51- 55. DOI: 10.13193/j.issn.1673-7717.2020.05.012. 李嘉, 高玲, 陈珊珊, 等. 健脾活血祛湿方通过干预AQP9表达调控线粒体细胞凋亡通路对荷H22肝癌移植瘤裸鼠的影响研究[J]. 中华中医药学刊, 2020, 38( 5): 51- 55. DOI: 10.13193/j.issn.1673-7717.2020.05.012.
[30]	CHAO X, ZHANG YF, LI H, et al. Molecular mechanism research on Beishen Zhuyu Formula inducing hepatocellular carcinoma HepG2 cells through mitochondria apoptosis pathway[J]. China J Tradit Chin Med Pharm, 2020, 35( 7): 3353- 3357. 晁旭, 张艳芳, 李宏, 等. 贝参茱萸方通过线粒体途径诱导人肝癌HepG2细胞凋亡的分子机制[J]. 中华中医药杂志, 2020, 35( 7): 3353- 3357.
[31]	LAN HY, AN P, LIU QP, et al. Aidi injection induces apoptosis of hepatocellular carcinoma cells through the mitochondrial pathway[J]. J Ethnopharmacol, 2021, 274: 114073. DOI: 10.1016/j.jep.2021.114073.
[32]	YANG M, SHEN C, ZHU SJ, et al. Chinese patent medicine Aidi injection for cancer care: An overview of systematic reviews and meta-analyses[J]. J Ethnopharmacol, 2022, 282: 114656. DOI: 10.1016/j.jep.2021.114656.
[33]	LIU D, ZHANG G, SHEN ZP, et al. Effect of Aidi injection combined with transcatheter arterial chemoembolization on clinical efficacy, vascular growth factor and cellular immune function in patients with primary liver cancer[J]. J Hainan Med Univ, 2019, 25( 23): 1770- 1775. DOI: 10.13210/j.cnki.jhmu.20191118.001. 刘东, 张罡, 沈忠培, 等. 艾迪注射液联合肝动脉化疗栓塞术对原发性肝癌患者的临床疗效、血管生长因子及细胞免疫功能的影响[J]. 海南医学院学报, 2019, 25( 23): 1770- 1775. DOI: 10.13210/j.cnki.jhmu.20191118.001.
[34]	WANG F, ZHANG C, ZHENG S. Preparation of triptolide TPP-PEG-PCL liposomes with mitochondrial targeting and its promotion apoptosis of hepatic tumor cells[J]. Chin Tradit Herb Drugs, 2021, 52( 24): 7473- 7483. DOI: 10.7501/j.issn.0253-2670.2021.24.009. 王锋, 张超, 郑栓. 具有线粒体靶向性的雷公藤甲素TPP-PEG-PCL脂质体的制备及其促肝肿瘤细胞凋亡研究[J]. 中草药, 2021, 52( 24): 7473- 7483. DOI: 10.7501/j.issn.0253-2670.2021.24.009.
[35]	MAO JX, YI M, TAO YY, et al. Costunolide isolated from Vladimiria souliei inhibits the proliferation and induces the apoptosis of HepG2 cells[J]. Mol Med Rep, 2019, 19( 2): 1372- 1379. DOI: 10.3892/mmr.2018.9736.
[36]	HU HX, CHEN XZ, CAO ZY, et al. The effect of Jiedu Xiaozhengyin on the expression of marker molecules CD90 and CD133 in liver cancer stem cells[J]. Pract Clin J Integr Tradit Chin West Med, 2015, 15( 5): 80- 82. DOI: 10.13638/j.issn.1671-4040.2015.05.049. 胡海霞, 陈旭征, 曹治云, 等. 解毒消癥饮对肝癌干细胞标记分子CD90和CD133表达的影响[J]. 实用中西医结合临床, 2015, 15( 5): 80- 82. DOI: 10.13638/j.issn.1671-4040.2015.05.049.
[37]	CHEN XZ, DU J. Effect of Jiedu Xiaozheng decoction on mitochondrial membrane potential of hepatoma HepG2 cells[J]. J Fujian Univ Tradit Chin Med, 2009, 19( 2): 22- 23. DOI: 10.3969/j.issn.1004-5627.2009.02.008. 陈旭征, 杜建. 解毒消癥饮对肝癌细胞株HepG2线粒体膜电位的影响[J]. 福建中医学院学报, 2009, 19( 2): 22- 23. DOI: 10.3969/j.issn.1004-5627.2009.02.008.
[38]	DONG ZY, QIU XT, KUJAWA S, et al. Cinobufacini injection for moderate and advanced primary liver cancer: A systematic review and meta-analysis[J]. J Chin Pharm Sci, 2019, 28( 4): 264- 275.
[39]	WU HL, CHEN JB, XU K, et al. Progress in antitumor effect and mechanism of Cinobufagin[J]. Chin J Clin Pharmacol, 2021, 37( 2): 192- 196. DOI: 10.13699/j.cnki.1001-6821.2021.02.024. 吴宏磊, 陈进宝, 徐可, 等. 华蟾素抗肿瘤作用及其机制研究进展[J]. 中国临床药理学杂志, 2021, 37( 2): 192- 196. DOI: 10.13699/j.cnki.1001-6821.2021.02.024.
[40]	CUI H, GAO QQ, WANG XQ, et al. Study on the inhibition of hepatoma cell proliferation by regulating the Bcl-2/CytC signaling pathway with hedyotis diffusticosa injection[J]. Shaanxi J Tradit Chin Med, 2019, 40( 4): 418- 420. DOI: 10.3969/j.issn.1000-7369.2019.04.003. 崔宏, 高琴琴, 王效谦, 等. 白花蛇舌草注射剂调节Bcl-2/CytC信号通路诱导线粒体凋亡抑制肝癌细胞增殖的研究[J]. 陕西中医, 2019, 40( 4): 418- 420. DOI: 10.3969/j.issn.1000-7369.2019.04.003.